Appelbaum Fr
- Hematology top 0.5%
- Hematopoietic Stem Cell Transplantation 30
- Acute Myeloid Leukemia Research 11
- Chronic Myeloid Leukemia Treatments 4
- Genetics top 5%
- Mesenchymal stem cell research 7
- Virus-based gene therapy research 4
- Oncology top 5%
- Transplantation top 5%
- Immunology top 10%
-
- Acute Lymphoblastic Leukemia research 9
-
- Hematological disorders and diagnostics 5
-
- Radiopharmaceutical Chemistry and Applications 4
- Cited by
- HematologyGeneticsOncology
- Journals
- Cancer Research (1 paper)Experimental Hematology (1 paper)PubMed (59 papers)
- Partner nations
- United StatesSouth Africa
In The Last Decade
Appelbaum Fr
61 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 78
- Hematology 1.3k
- Genetics 210
- Oncology 515
- Transplantation 47
- Immunology 295
Countries citing papers authored by Appelbaum Fr
This map shows the geographic impact of Appelbaum Fr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Appelbaum Fr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Appelbaum Fr more than expected).
Fields of papers citing papers by Appelbaum Fr
This network shows the impact of papers produced by Appelbaum Fr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Appelbaum Fr. The network helps show where Appelbaum Fr may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Appelbaum Fr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Antibody-targeted therapy for myeloid leukemia. | 1999 | 46 |
| 2 | Introduction: emerging therapies for hematologic malignancies: antibodies, antisense, and cytokine approaches | 1999 | 3 |
| 3 | Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). | 1997 | 41 |
| 4 | Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. | 1995 | 51 |
| 5 | Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia. | 1995 | 34 |
| 6 | Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321. | 1994 | 3 |
| 7 | Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. | 1994 | 35 |
| 8 | Autologous bone marrow transplantation for acute lymphoblastic leukemia. | 1993 | 29 |
| 9 | Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. | 1991 | 25 |
| 10 | Effects of treatment regimens on post marrow transplant relapse. | 1991 | 9 |
| 11 | Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy. | 1991 | 25 |
| 12 | Sensitivity of newly transplanted marrow to further irradiation. | 1988 | 3 |
| 13 | Marrow transplantation for hematologic malignancies: a brief review of current status and future prospects. | 1988 | 19 |
| 14 | Use of iodine-131-labeled anti-immune response-associated monoclonal antibody as preparative regimen prior to bone marrow transplantation: initial dosimetry. | 1987 | 7 |
| 15 | Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. | 1987 | 25 |
| 16 | Phase I study of high-dose dimethylbusulfan followed by autologous bone marrow transplantation in patients with advanced malignancy. | 1987 | 8 |
| 17 | Marrow harvesting for autologous marrow transplantation. | 1985 | 23 |
| 18 | Fatal hepatotoxicity associated with AMSA therapy. | 1982 | 10 |
| 19 | Hemopoietic reconstitution following autologous bone marrow and peripheral blood mononuclear cell infusions. | 1979 | 23 |
| 20 | Sequential combination chemotherapy (containing high-dose cyclophosphamide) for metastic osteogenic sarcoma. | 1978 | 4 |
About Appelbaum Fr
Appelbaum Fr is a scholar working on Hematology, Genetics and Emergency Medicine, having authored 61 papers that have together received 1.7k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (30 papers), Acute Myeloid Leukemia Research (11 papers), Acute Lymphoblastic Leukemia research (9 papers), Mesenchymal stem cell research (7 papers), Hematological disorders and diagnostics (5 papers), Virus-based gene therapy research (4 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). The work is most often cited by research in Hematology (1.3k citations), Genetics (210 citations) and Oncology (515 citations). Appelbaum Fr has collaborated with scholars based in United States and South Africa. Frequent co-authors include CD Buckner, Rainer Storb, JE Sanders, Clift Ra, K Doney, Thomas Ed, Jack W. Singer, Deeg Hj, Petersen Fb and A Fefer. Their work appears in journals such as Cancer Research, Experimental Hematology and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.